Mostrar el registro sencillo del ítem
| dc.contributor.author | Lourenço Paiva, Bruno | |
| dc.contributor.author | Paíno Gómez, María Teresa | |
| dc.contributor.author | Sayagués Manzano, José María | |
| dc.contributor.author | Garayoa Berrueta, Mercedes | |
| dc.contributor.author | San Segundo, Laura | |
| dc.contributor.author | Martín Alonso, María Montserrat | |
| dc.contributor.author | Mota, Ines | |
| dc.contributor.author | Sánchez, María Luz | |
| dc.contributor.author | Bárcena, Paloma | |
| dc.contributor.author | Aires-Mejía, Irene | |
| dc.contributor.author | Corchete Sánchez, Luis Antonio | |
| dc.contributor.author | Jimenez, Cristina | |
| dc.contributor.author | García Sanz, Ramón | |
| dc.contributor.author | Gutiérrez Gutiérrez, Norma Carmen | |
| dc.contributor.author | Ocio San Miguel, Enrique M. | |
| dc.contributor.author | Mateos Manteca, María Victoria | |
| dc.contributor.author | Vidriales Vicente, María Belén | |
| dc.contributor.author | Orfao de Matos Correia e Vale, José Alberto | |
| dc.contributor.author | San Miguel Izquierdo, Jesús Fernando | |
| dc.date.accessioned | 2024-01-30T09:29:58Z | |
| dc.date.available | 2024-01-30T09:29:58Z | |
| dc.date.issued | 2013-11-21 | |
| dc.identifier.citation | Paiva, B., Paino, T., Sayagues, J. M., Garayoa, M., San-Segundo, L., Martín, M., ... & San Miguel, J. F. (2013). Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood, The Journal of the American Society of Hematology, 122(22), 3591-3598. https://doi.org/10.1182/blood-2013-06-510453 | es_ES |
| dc.identifier.issn | 0006-4971 | |
| dc.identifier.uri | http://hdl.handle.net/10366/154966 | |
| dc.description.abstract | [EN]Circulating myeloma tumor cells (CTCs) as defined by the presence of peripheral blood (PB) clonal plasma cells (PCs) are a powerful prognostic marker in multiple myeloma (MM). However, the biological features of CTCs and their pathophysiological role in MM remains unexplored. Here, we investigate the phenotypic, cytogenetic, and functional characteristics as well as the circadian distribution of CTCs vs paired bone marrow (BM) clonal PCs from MM patients. Our results show that CTCs typically represent a unique subpopulation of all BM clonal PCs, characterized by downregulation (P < .05) of integrins (CD11a/CD11c/CD29/CD49d/CD49e), adhesion (CD33/CD56/CD117/CD138), and activation molecules (CD28/CD38/CD81). Fluorescence in situ hybridization analysis of fluorescence-activated cell sorter-sorted CTCs also unraveled different cytogenetic profiles vs paired BM clonal PCs. Moreover, CTCs were mostly quiescent and associated with higher clonogenic potential when cocultured with BM stromal cells. Most interestingly, CTCs showed a circadian distribution which fluctuates in a similar pattern to that of CD34(+) cells, and opposite to stromal cell-derived factor 1 plasma levels and corresponding surface expression of CXC chemokine receptor 4 on clonal PCs, suggesting that in MM, CTCs may egress to PB to colonize/metastasize other sites in the BM during the patients' resting period. | es_ES |
| dc.format.mimetype | application/pdf | |
| dc.language.iso | eng | es_ES |
| dc.publisher | American Society of Hematology | es_ES |
| dc.subject | Myeloma | es_ES |
| dc.subject | Circulating tumor cells | es_ES |
| dc.subject.mesh | Plasma Cells | * |
| dc.subject.mesh | Prognosis | * |
| dc.subject.mesh | Antigens | * |
| dc.subject.mesh | Immunophenotyping | * |
| dc.subject.mesh | Multiple Myeloma | * |
| dc.subject.mesh | Prospective Studies | * |
| dc.subject.mesh | Cell Cycle | * |
| dc.subject.mesh | Humans | * |
| dc.subject.mesh | Circadian Rhythm | * |
| dc.subject.mesh | Cytogenetic Analysis | * |
| dc.subject.mesh | Tumor Stem Cell Assay | * |
| dc.title | Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
| dc.relation.publishversion | https://doi.org/10.1182/blood-2013-06-510453 | es_ES |
| dc.subject.unesco | 3209 Farmacología | es_ES |
| dc.identifier.doi | 10.1182/blood-2013-06-510453 | |
| dc.relation.projectID | RD12/0036/0071 | es_ES |
| dc.relation.projectID | RD12/0036/0058 | es_ES |
| dc.relation.projectID | RD12/0036/0048 | es_ES |
| dc.relation.projectID | RD12/ 0036/0069 | es_ES |
| dc.relation.projectID | PI060339 | es_ES |
| dc.relation.projectID | 06/1354 | es_ES |
| dc.relation.projectID | 02/0905 | es_ES |
| dc.relation.projectID | 01/0089/01-02 | es_ES |
| dc.relation.projectID | PS09/01897/01370 | es_ES |
| dc.relation.projectID | PI112/02311 | es_ES |
| dc.relation.projectID | GCB120981SAN | es_ES |
| dc.relation.projectID | Fundación Memoria de D. Samuel Solórzano Barruso | es_ES |
| dc.relation.projectID | Multiple Myeloma Research Foundation | es_ES |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
| dc.identifier.pmid | 24072855 | |
| dc.identifier.essn | 1528-0020 | |
| dc.journal.title | Blood | es_ES |
| dc.volume.number | 122 | es_ES |
| dc.issue.number | 22 | es_ES |
| dc.page.initial | 3591 | es_ES |
| dc.page.final | 3598 | es_ES |
| dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
| dc.subject.decs | ritmo circadiano | * |
| dc.subject.decs | inmunofenotipificación | * |
| dc.subject.decs | pronóstico | * |
| dc.subject.decs | ciclo celular | * |
| dc.subject.decs | análisis citogenético | * |
| dc.subject.decs | humanos | * |
| dc.subject.decs | células plasmáticas | * |
| dc.subject.decs | análisis de células madre tumorales | * |
| dc.subject.decs | mieloma múltiple | * |
| dc.subject.decs | antígenos | * |
| dc.subject.decs | estudios prospectivos | * |









;